CareDx AlloHeme Detects Relapse 41 Days Earlier with 85% Sensitivity, 92% Specificity
CareDx’s AlloHeme achieved 85% sensitivity and 92% specificity in the ACROBAT study, detecting AML and MDS relapses a median of 41 days earlier than standard testing. The company plans CLIA readiness in 2026, U.S. commercialization in 2027 and anticipates payer coverage by 2028 under its Transplant+ strategy.
1. AlloHeme Clinical Validation
The ACROBAT observational study spanned 11 U.S. transplant centers with 198 evaluable patients and 40 relapse events. AlloHeme delivered 85% sensitivity, 92% specificity, 95% negative predictive value and detected relapses a median of 41 days earlier than conventional diagnosis, enabling potential earlier intervention.
2. Commercialization Plan
CareDx aims for CLIA readiness in 2026, national U.S. commercialization in 2027 and anticipated payer coverage by 2028. These milestones form the core of its Transplant+ strategy to extend diagnostics beyond solid organ transplants into cell therapy and hematologic oncology markets.
3. Strategic Impact and Market Opportunity
Early relapse detection addresses the leading cause of mortality in post-transplant AML and MDS patients and may support preemptive treatment strategies. This capability aligns with a cell therapy market valued at $9.13 billion in 2026 and projected 22.9% CAGR through 2034, bolstering CareDx’s long-term growth prospects.